Craig Hendrix, MD, DABCP, FCP, is Professor Emeritus and former Wellcome Professor and Director, Division of Clinical Pharmacology, at The Johns Hopkins University. He joined Oak Crest Institute of Science in Monrovia, CA, as Senior Faculty (part-time) in February 2025 upon his retirement from Hopkins. Craig graduated from the Massachusetts Institute of Technology and Georgetown University School of Medicine before entering Johns Hopkins for post-graduate training in internal medicine, infectious diseases, and clinical pharmacology. He served over 12 years in the US Air Force, including 10 years on the faculty of the Uniformed Services University of Health Sciences. Since returning to Johns Hopkins, he’s served on the faculty for 30 years.
Dr. Hendrix’s primary research focus has been the clinical pharmacology of HIV pre-exposure prophylaxis. He’s served as Principal Investigator of over 100 clinical studies (mostly phase 1) and, in addition, served as the Protocol Pharmacologist for over 80 clinical trials (mostly phase 2 and 3). He has authored over 350 scientific papers, studying over 90 drugs. He founded PRIÖNDE Biopharma, LLC, in 2020, focused on topical microbicide development for HIV pre-exposure prophylaxis.
Formerly, he directed the post-doctoral T32 Clinical Pharmacology Training Program at Johns Hopkins and received awards at Hopkins for both teaching and mentoring. Currently, he is Chairman of the American Board of Clinical Pharmacology, which accredits clinical pharmacology fellowship training programs and administers the national board examination in Clinical Pharmacology.
Dr. Hendrix served on a National Academy of Medicine Advisory Panel, CDC Board of Scientific Counselors, several FDA Advisory Committees, and the boards of the American College of Clinical Pharmacology (ACCP) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT). He has received awards for scientific excellence from the PhRMA Foundation, ASCPT/FDA, and ACCP.
